GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (NAS:GTBP) » Definitions » Equity-to-Asset

GT Biopharma (GT Biopharma) Equity-to-Asset : 0.54 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is GT Biopharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. GT Biopharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $5.31 Mil. GT Biopharma's Total Assets for the quarter that ended in Mar. 2024 was $9.91 Mil.

The historical rank and industry rank for GT Biopharma's Equity-to-Asset or its related term are showing as below:

GTBP' s Equity-to-Asset Range Over the Past 10 Years
Min: -933.33   Med: 0.38   Max: 0.99
Current: 0.54

During the past 13 years, the highest Equity to Asset Ratio of GT Biopharma was 0.99. The lowest was -933.33. And the median was 0.38.

GTBP's Equity-to-Asset is ranked worse than
61.26% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs GTBP: 0.54

GT Biopharma Equity-to-Asset Historical Data

The historical data trend for GT Biopharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GT Biopharma Equity-to-Asset Chart

GT Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -48.34 -5.20 0.68 0.70 0.53

GT Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.65 0.62 0.53 0.54

Competitive Comparison of GT Biopharma's Equity-to-Asset

For the Biotechnology subindustry, GT Biopharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Equity-to-Asset falls into.



GT Biopharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

GT Biopharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=7.476/14.109
=

GT Biopharma's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=5.312/9.912
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GT Biopharma  (NAS:GTBP) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


GT Biopharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of GT Biopharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


GT Biopharma (GT Biopharma) Business Description

Traded in Other Exchanges
Address
8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Executives
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Michael Martin Breen director, officer: Exec. Chair. and Interim CEO LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU
Manu Ohri officer: CFO & Secretary 2355 MAIN STREET, SUITE 120, IRVINE CA 92614
Bruce Wendel director 70 ELEVEN O'CLOCK ROAD, WESTON CT 06883
Gregory Berk officer: Pres. of R&D, CMO HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Alan Louis Urban director 1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404
Gavin Choy officer: Acting Chief Financial Officer 8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005
Steven W Weldon director, officer: CFO 7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835
Shawn Cross director, officer: Chief Executive Officer 1825 K STREET SUITE 510, WASHINGTON DC 20006
Raymond W. Urbanski officer: Chief Medical Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Kathleen Clarence-smith director, 10 percent owner, officer: CEO 1623 31ST STREET NW, WASHINGTON DC 20007
Mark J Silverman 10 percent owner 224 22ND ST., SANTA MONICA CA 90402
Bristol Capital Llc 10 percent owner
Bristol Investment Fund Ltd 10 percent owner 89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205